Several potential therapeutic genes were discovered in this unique tumor subset, such as TOX2 and CD38. We next reconstructed the tumor microenvironment (TME) of HSTCL, and investigated how the TME were interacting with tumor cells and reforming under therapeutic conditions. This evidence concerns the gene CD38 and neoplasm.